  |
||||||||
|
Orchid Chemicals & Pharmaceuticals Ltd. |
||||||||
|
Audited Financial Results for the year ended March 31, 2007
|
||||||||
| S.No |
Particulars
|
Nine months ended
31-Dec-06 (unaudited) |
Three Months ended
31-Mar-07 (unaudited) |
Three
Months ended
31-Mar-06 (unaudited)
|
Year ended
31-Mar-07 (Audited)
|
Year ended
31-Mar-06 (Audited)
|
Consolidated year ended
31-Mar-07 (Audited)
|
Consolidated year ended
31-Mar-06 (Audited)
|
|
1
|
Sales and Operating Income |
68617.44
|
24800.11
|
23984.87
|
93417.55
|
88876.64 |
98508.07
|
95193.99
|
|
2
|
Other Income |
126.56
|
29.42
|
100.49
|
155.98
|
132.73
|
35.62
|
121.90
|
|
3
|
Total Expenditure |
47250.32
|
17186.65
|
17074.52
|
64436.97
|
62949.30
|
70849.98
|
71448.65
|
|
a) Decrease/(Increase) in Stock in trade |
(12862.76)
|
(1149.34)
|
2095.59
|
(14012.10)
|
(1912.72)
|
(13745.93)
|
(2048.83)
|
|
| b) Material Cost |
35988.08
|
9079.57
|
7178.97
|
45067.65
|
38319.74
|
49109.64
|
44889.92
|
|
| c) Staff Cost |
5734.23
|
2038.54
|
1775.85
|
7772.77
|
6521.18
|
9244.85
|
6963.89
|
|
| d) Other Expenditure |
18390.77
|
7217.88
|
6024.11
|
25608.65
|
20021.10
|
26241.42
|
21643.67
|
|
|
4
|
Profit before Interest, Depreciation & Tax
(1+2-3)
|
21493.68
|
7642.88
|
7010.84
|
29136.56
|
26060.07
|
27693.71
|
23867.24
|
|
5
|
Interest and Finance Charges |
7406.35
|
2424.30
|
2003.83
|
9830.65
|
8701.32
|
9929.14
|
8784.48
|
|
6
|
Depreciation/Amortisation |
5979.82
|
2266.91
|
2607.39
|
8246.73
|
8297.57
|
8508.93
|
8581.74
|
|
7
|
Profit before tax |
8107.51
|
2951.67
|
2399.62
|
11059.18
|
9061.18
|
9255.64
|
6501.02
|
|
8
|
Provision for Taxation |
|
|
|
|
|||
| - Current Tax |
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
| - Deferred Tax |
750.00
|
480.00
|
410.00
|
1230.00
|
590.00
|
1230.00
|
590.00
|
|
| - Fringe Benefit Tax | 121.00 |
45.00 |
51.00 |
166.00 |
181.00 |
166.00 |
181.00 |
|
|
9
|
Net Profit (7-8) |
7236.51
|
2426.67
|
1938.62
|
9663.18
|
8290.18
|
7859.64
|
5730.02
|
|
10
|
Paid- up Equity Share Capital (Face value of Rs. 10 each) |
6581.57
|
6581.63
|
6461.82
|
6581.63
|
6461.82
|
6581.63
|
6461.82
|
|
11
|
Reserves excluding Revaluation Reserves |
|
|
|
43509.59
|
72040.72
|
41524.32
|
71096.90
|
|
12
|
Basic Earnings per Share (EPS) Rs. |
11.01
|
3.69
|
3.47*
|
14.70
|
14.85
|
11.96
|
10.27
|
|
13
|
Diluted Earnings per share (EPS) Rs.
|
9.84
|
3.31
|
3.19*
|
13.19
|
13.64
|
10.72
|
9.43
|
| 14 |
Aggregate of Public Shareholding |
50833619 |
53124009 |
|||||
|
77.24
|
82.21
|
|||||||
| *EPS is for the period (not annualised) after providing for taxes | ||||||||
| 1 | The above financial results were adopted by the Board of Directors at its meeting held on Thursday, May 03, 2007. | |||||||||
| 2 | The Board of Directors has recommended a dividend of 30% (Rs 3/-per share) on the equity share of Rs 10/- each. | |||||||||
| 3 | The Allotment Committee of the Board has allotted: - 175,000 Zero Coupon Foreign Currency Convertible Bonds (FCCBs) aggregating to US$ 175,000,000 on February 27, 2007 - 5,000,000 warrants to Promoter / Promoter Group at a price of Rs.202.58 per warrant on March 01, 2007, each warrant convertible into one equity share of Rs 10/- each. - 550 shares to employees under ORCHID ESOP Scheme, on January 19, 2007. - 6085 shares to employees under ORCHID ESOP Scheme, on May 03, 2007. |
|||||||||
| 4 | The Reserves and Surplus at the end of the year is after adjusting Rs.36371.36 lakhs being issue expenses and the premium payable |
|||||||||
| 5 | In view of deferrment of date of implementation of revised AS15 by ICAI, the new AS15 will be implemented from the financial year 2007-08 | |||||||||
| 6 | The Company is operating in a single segment i.e., "Pharmaceuticals". | |||||||||
| 7 | The Company received 16 complaints during the quarter ended March 31, 2007 from the shareholders. All the complaints have been resolved and no complaints were pending as on March 31, 2007. | |||||||||
| 8 | Previous period figures have been regrouped wherever necessary. |
|||||||||
|
||||||||||